References
- World Health Organization. The global burden of disease: 2004 update [Internet]. Geneva, Switzerland: WHO Press; 2008. Available from: http://www.who.int/healthinfo/global_burden_disease/GBD_report_4update_full.pdf (accessed 21 December 11).
- Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007 Sep 1;370(9589):765–773.
- Vestbo J, Hurd SS, Agusti AG, Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease, GOLD Executive Summary. Am J Respir Crit Care Med 2013 Feb;187(4):347–365.
- Fuhr R, Magnussen H, Sarem K, Efficacy of aclidinium bromide 400 microgram twice daily compared with placebo and tiotropium in patients with moderate to severe COPD. Chest 2012 Mar;141(3):745–752.
- Singh D, Magnussen H, Kirsten A, A randomised, placebo- and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patients. Pulm Pharmacol Ther 2012 Jun;25(3):248–253.
- Kerwin EM, D’Urzo AD, Gelb AF, Lakkis H, Garcia Gil E, Caracta CF. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD 2012 Apr;9(2):90–101.
- Jones PW, Singh D, Bateman ED, Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J 2012 Mar;40(4):830–836.
- Miller MR, Hankinson J, Brusasco V, Standardisation of spirometry. Eur Respir J 2005 Aug;26(2):319–338.
- Jones PW. St. George's Respiratory Questionnaire: MCID. COPD 2005 Mar;2(1):75–79.
- Huiart L, Ernst P, Suissa S. Cardiovascular morbidity and mortality in COPD. Chest 2005 Oct;128(4):2640–2646.
- Sentellas S, Ramos I, Alberti J, Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites. Eur J Pharm Sci 2010 Mar;39(5):283–290.
- Jansat JM, Lamarca R, Garcia Gil E, Ferrer P. Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects. Int J Clin Pharmacol Ther 2009 Jul;47(7):460–468.
- Jansat JM, Lamarca R, de Miquel G, Schrodter A, Miletzki B, Gurniak M. Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants. J Clin Pharmacol 2009 Oct;49(10):1239–1246.
- Lasseter K, Dilzer S, Jansat JM, Garcia Gil E, Caracta C, Ortiz S. Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers. Pulm Pharmacol Ther 2012;25(2):193–199.
- Mahler DA, Tomlinson D, Olmstead EM, Tosteson AN, O’Connor GT. Changes in dyspnea, health status, and lung function in chronic airway disease. Am J Respir Crit Care Med 1995 Jan;151(1):61–65.
- Hajiro T, Nishimura K, Tsukino M, Ikeda A, Oga T, Izumi T. A comparison of the level of dyspnea vs disease severity in indicating the health-related quality of life of patients with COPD. Chest 1999 Dec;116(6):1632–1637.
- Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000 May 13;320(7245):1297–1303.
- Tashkin DP, Celli B, Senn S, A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008 Oct 9;359(15):1543–1554.
- Calverley PM, Anderson JA, Celli B, Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007 Feb 22;356(8):775–789.